N/A N=298 Application of Bioimpedance Spectroscopy in Taiwan Dialysis Patients
Fluid Overload
Primary: All-cause Hospitalization — 0.52; 0.54 hospitalizations per patient-year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Helicobacter Pylori Infection
Primary: Eradication of H Pylori Infection 4 Weeks After Completion of Therapy — 23; 26 participants
Phase 1 N=27 Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
Memory Impairment · Alzheimer's Disease
Primary: Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Delayed Recall at 1 Hour After Scopolamine Administration — -6.7; -7.0…
N/A N=42 Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A
Hemophilia A
Primary: Percentage of Participants by Family History of Factor VIII Inhibitor — 0; 100.0 percentage of participants
Phase 2 N=60 A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
Ulcerative Colitis
Primary: Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT — 8; 8 Participants — p=0.7532
Phase 3 N=72 Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With >= 50% Improvement in GERD Health Related Quality of Life (GERD-HRQL - Velanovich) Score — 73 percentage of total participants
N/A N=615 Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease
Parkinson Disease
Primary: Percentage of Adverse Drug Reactions — 24.78 percentage of participants
Phase 2 N=41 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Squamous Cell Carcinoma of Mouth · Intraepithelial Neoplasia
Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048
N/A N=263 Confirmatory Clinical Trial of the Evera MRI System for Conditionally-safe MRI Access
Implantable Defibrillator
Primary: MRI-related Events — 147 Participants free of MRI-related events — p=<0.0001
Phase 2 N=165 The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
Actinic Keratoses
Primary: Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance. — 22; 17; 19; 25 participants — p=0.60
Phase 2 N=38 Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
Pancreatic Neoplasms · Adenocarcinoma
Primary: Anti-tumor Effect as Measured by the Proportion of Patients Free of Disease-progression at Six Months After Treatment Initiation — 28; 14 percent of patients with PFS
Phase 2 N=59 Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects
Intubated and Mechanically Ventilated Pediatric Subjects
Primary: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) — 2681.332; 6460.576; 16992.540; 28531.864 picograms*hr/mL
Phase 4 N=90 Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation
Ultrasound · CT Scans · MRIs
Primary: Number of Subjects Who Had Success in Sedation — 0; 2; 0; 0 participants
N/A N=345 Project SERVE: Post Deployment Functioning
Post-traumatic Stress Disorder · Depressive Disorder · Alcoholism
Primary: World Health Organization Disability Assessment Schedule II (WHODAS II) — 1.87; 2.03; 2.07; 1.88 units on a scale
Phase 3 N=424 A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Breast Cancer
Primary: Progression Free Survival (PFS) — 13.7; 16.5 months — p=0.0775